Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year. Standard CHOP chemotherapy improves five-year survival to 70%—still a ...

Combined efficacy of chemotherapy and ultrasound found to elevate brain cancer survival by 40%, making medications work ...

A study of 6,800 colon cancer patients found those who took Ozempic or Mounjaro were more likely to survive the disease. It may boil down to inflammation.

ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

After a median 9.6 months of cabozantinib treatment, the 6-month brain metastasis progression-free rate was 56%, meeting the study’s primary endpoint.

Jennifer Hipple is a Lancaster resident who works in health care and has been a longtime year-round volunteer with the ...

DENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had ...

A clinical oncology research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-α (HIF-2α) inhibitors are poised to ...

Dr. Joshua Sabai spoke with Dr. Chandler Park about the latest advances in kidney cancer, highlighting clinical trials that are shaping care for patients.

A clinical oncology research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with ...

DENVER -- A discussion about patient-centered issues in kidney cancer management focused considerable attention on the controversial antiparasitic ivermectin, which was not even on the program at the ...